[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2014153166A3 - Therapeutic use of antibodies to hgf - Google Patents

Therapeutic use of antibodies to hgf Download PDF

Info

Publication number
WO2014153166A3
WO2014153166A3 PCT/US2014/029383 US2014029383W WO2014153166A3 WO 2014153166 A3 WO2014153166 A3 WO 2014153166A3 US 2014029383 W US2014029383 W US 2014029383W WO 2014153166 A3 WO2014153166 A3 WO 2014153166A3
Authority
WO
WIPO (PCT)
Prior art keywords
hgf
antibodies
therapeutic use
hgfs
paricularly
Prior art date
Application number
PCT/US2014/029383
Other languages
French (fr)
Other versions
WO2014153166A2 (en
Inventor
Leon F. GARCIA-MARTINEZ
Andrew L. Feldhaus
Katie ANDERSON
Benjamin H. Dutzar
John A. Latham
Original Assignee
Alder Biopharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alder Biopharmaceuticals, Inc. filed Critical Alder Biopharmaceuticals, Inc.
Publication of WO2014153166A2 publication Critical patent/WO2014153166A2/en
Publication of WO2014153166A3 publication Critical patent/WO2014153166A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention is directed to antibodies and fragments thereof (especially chimeric and humanized) having binding specificity for HGF and their use in therapy and diagnosis. These antibodies inhibit or block HGF-associated activities including HGFs effects on cell proliferation, invasion, angiogenesis, metastasis and fibrosis. Paricularly the antibodies may be used as a monotherapy or in combination therapies in treating cancer, other proliferative disorders and other conditions wherein inhibition of HGF and/or the HGF/HGF-R (c-met) interaction is desired.
PCT/US2014/029383 2013-03-14 2014-03-14 Therapeutic use of antibodies to hgf WO2014153166A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361782868P 2013-03-14 2013-03-14
US201361781643P 2013-03-14 2013-03-14
US61/781,643 2013-03-14
US61/782,868 2013-03-14

Publications (2)

Publication Number Publication Date
WO2014153166A2 WO2014153166A2 (en) 2014-09-25
WO2014153166A3 true WO2014153166A3 (en) 2014-12-04

Family

ID=51581767

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2014/029163 WO2014153117A2 (en) 2013-03-14 2014-03-14 Antibodies to hgf and compositions containing
PCT/US2014/029383 WO2014153166A2 (en) 2013-03-14 2014-03-14 Therapeutic use of antibodies to hgf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2014/029163 WO2014153117A2 (en) 2013-03-14 2014-03-14 Antibodies to hgf and compositions containing

Country Status (7)

Country Link
EP (1) EP2964673A4 (en)
JP (1) JP2016516052A (en)
KR (1) KR20150140685A (en)
CN (1) CN105246915A (en)
CA (1) CA2904743A1 (en)
TW (2) TW201438737A (en)
WO (2) WO2014153117A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106699868B (en) * 2017-03-01 2019-11-15 牡丹江医学院 A kind of protein and the nucleotide sequence for encoding it
CN109771642B (en) * 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET agonistic antibodies and uses thereof
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
CN112569359A (en) * 2019-09-30 2021-03-30 上海生物制品研究所有限责任公司 Application of interferon and protooncogene product targeted inhibitor in synergistic treatment of kidney cancer
CA3160091A1 (en) 2019-11-05 2021-05-14 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
WO2022228514A1 (en) * 2021-04-29 2022-11-03 北京浩古元方生物医药科技有限公司 Anti-human leukemia inhibitory factor antibody and use thereof
WO2024129564A1 (en) * 2022-12-13 2024-06-20 The Children's Medical Center Corporation Methods and compositions for the treatment of vascular anomalies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US7718174B2 (en) * 2006-07-14 2010-05-18 Abxign, Inc. Anti-HGF/SF humanized antibody
US20100129357A1 (en) * 2008-11-25 2010-05-27 Leon Garcia-Martinez Antibodies to il-6 and use thereof
US20100278815A1 (en) * 2006-04-01 2010-11-04 Galaxy Biotech, Llc Humanized Monoclonal Antibodies to Hepatocyte Growth Factor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
SI1648998T1 (en) * 2003-07-18 2015-01-30 Amgen Inc. Specific binding agents to hepatocyte growth factor
JP5607357B2 (en) * 2006-05-19 2014-10-15 アルダー・バイオファーマシューティカルズ・インコーポレーテッド Culture method for obtaining a clonal population of antigen-specific B cells
US7659378B2 (en) * 2006-06-02 2010-02-09 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
MX2008014829A (en) * 2006-06-02 2009-01-29 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins.
CN101460520B (en) * 2006-06-02 2012-12-26 Aveo制药公司 Hepatocyte growth factor (hgf) binding proteins
US9539324B2 (en) * 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US20100278815A1 (en) * 2006-04-01 2010-11-04 Galaxy Biotech, Llc Humanized Monoclonal Antibodies to Hepatocyte Growth Factor
US7718174B2 (en) * 2006-07-14 2010-05-18 Abxign, Inc. Anti-HGF/SF humanized antibody
US20100129357A1 (en) * 2008-11-25 2010-05-27 Leon Garcia-Martinez Antibodies to il-6 and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BURGESS ET AL.: "Fully Human Monoclonal Antibodies to Hepatocyte Growth Factor with Therapeutic Potential against Hepatocyte Growth Factor/c-Met-Dependent Human Tumors", CANCER RESEARCH, vol. 66, 1 February 2006 (2006-02-01), pages 1721 - 1729, XP008075112, DOI: doi:10.1158/0008-5472.CAN-05-3329 *

Also Published As

Publication number Publication date
WO2014153117A9 (en) 2014-11-27
EP2964673A2 (en) 2016-01-13
WO2014153117A2 (en) 2014-09-25
KR20150140685A (en) 2015-12-16
TW201438737A (en) 2014-10-16
WO2014153166A2 (en) 2014-09-25
WO2014153117A3 (en) 2015-01-08
CN105246915A (en) 2016-01-13
JP2016516052A (en) 2016-06-02
TW201444868A (en) 2014-12-01
CA2904743A1 (en) 2014-09-25
EP2964673A4 (en) 2017-02-22

Similar Documents

Publication Publication Date Title
WO2014153166A3 (en) Therapeutic use of antibodies to hgf
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX2020011772A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer.
EP3365062A4 (en) Methods of treating solid or lymphatic tumors by combination therapy
DK3791896T5 (en) COMBINATION THERAPY WITH ANTIBODIES AGAINST CLAUDIN 18.2 FOR THE TREATMENT OF CANCER
WO2014151680A8 (en) Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
MX2016006726A (en) Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy.
PH12016500878B1 (en) Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2013056148A3 (en) Scd1 antagonists for treating cancer
WO2016055432A3 (en) Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents
MX2016002645A (en) Combination therapy for the treatment of glioblastoma.
MX2016015181A (en) Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer.
JO3097B1 (en) c-Met Antibodies
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
WO2013123432A3 (en) Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
WO2015127134A3 (en) Complement component c5 antibodies
IN2014DN06792A (en)
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX2018008105A (en) Metalloenzyme inhibitor compounds.
MX2017003211A (en) Anti-met antibodies and compositions.
MX360189B (en) Combination therapy for the treatment of glioblastoma.
MX2019013808A (en) Compounds for treatment of cancer.
WO2016066634A3 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
WO2014080286A3 (en) Methods and compositions for treating multiple sclerosis and related disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14768665

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14768665

Country of ref document: EP

Kind code of ref document: A2